Potassium channel modulators and schizophrenia: an overview of investigational drugs

References

• American Psychiatric Association (Ed.). Diagnostic and statistical manual of mental disorders: DSM-5-TR. Fifth. Text revision). Washington, DC: American Psychiatric Association Publishing. 2022.
   Google Scholar
• Patel KR, Cherian J, Gohil K, et al. Schizophrenia: overview and treatment options. P T. 2014;39(9):638–645.
   PubMedGoogle Scholar
• Kadakia A, Catillon M, Fan Q, et al. The economic burden of Schizophrenia in the United States. J Clin Psychiatry. 2022;83:22m14458.
   PubMed Web of Science ®Google Scholar
• Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry. 2012;25(2):83–88.
   PubMed Web of Science ®Google Scholar
• Haddad PM, Correll CU. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018;8(11):303–318.
   PubMed Web of Science ®Google Scholar
• Potkin SG, Kane JM, Correll CU, et al. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr. 2020;6(1):1. DOI:10.1038/s41537-019-0090-z
   PubMed Web of Science ®Google Scholar
• Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519–534.
   PubMed Web of Science ®Google Scholar
• Krause M, Zhu Y, Huhn M, et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2018;268(7):625–639. DOI:10.1007/s00406-018-0869-3
   PubMed Web of Science ®Google Scholar
• Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81(5):617–622.
   PubMed Web of Science ®Google Scholar
• Correll CU, Abi-Dargham A, Howes O. Emerging Treatments in Schizophrenia. J Clin Psychiatry. 2022;83(1):SU21204IP1.
   PubMed Web of Science ®Google Scholar
• Gomes FV, Grace AA. Beyond dopamine receptor antagonism: new targets for Schizophrenia treatment and prevention. Int J Mol Sci. 2021;22:4467.
   PubMed Web of Science ®Google Scholar
• Brannan SK, Sawchak S, Miller AC, et al. Muscarinic cholinergic receptor agonist and Peripheral Antagonist for Schizophrenia. N Engl J Med. 2021;384(8):717–726. DOI:10.1056/NEJMoa2017015
   PubMed Web of Science ®Google Scholar
• Stahl S. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate. CNS Spectr. 2018;23(3):187–191.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull. 1976;2(1):19–76.
   PubMed Web of Science ®Google Scholar
• McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020;19:15–33.
   PubMed Web of Science ®Google Scholar
• Mitra S, Mahintamani T, Kavoor AR, et al. Negative symptoms in schizophrenia. Ind Psychiatry J. 2016;25(2):135–144. DOI:10.4103/ipj.ipj_30_15
   PubMedGoogle Scholar
• Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J Psychiatry. 2004;185(3):196–204.
   PubMedGoogle Scholar
• Howes O, Bose S, Turkheimer F, et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatry. 2011;16(9):885–886. DOI:10.1038/mp.2011.20
   PubMed Web of Science ®Google Scholar
• McCutcheon R, Beck K, Jauhar S, et al. Defining the locus of dopaminergic dysfunction in Schizophrenia: a meta-analysis and test of the mesolimbic hypothesis. Schizophr Bull. 2018;44(6):1301–1311. DOI:10.1093/schbul/sbx180
   PubMed Web of Science ®Google Scholar
• McCutcheon RA, Abi-Dargham A, OD H. Schizophrenia, Dopamine and the striatum: from biology to symptoms. Trends Neurosci. 2019;42(3):205–220.
   PubMed Web of Science ®Google Scholar
• Jauhar S, Veronese M, Nour MM, et al. Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study. Mol Psychiatry. 2019;24(10):1502–1512. DOI:10.1038/s41380-018-0042-4
   PubMed Web of Science ®Google Scholar
• Uno Y, Coyle JT. Glutamate hypothesis in schizophrenia. Psychiatry Clin Neurosci. 2019;73(5):204–215.
   PubMed Web of Science ®Google Scholar
• Powers AR, Gancsos MG, Finn ES, et al. Ketamine-Induced Hallucinations. Psychopathology. 2015;48(6):376–385. DOI:10.1159/000438675
   PubMed Web of Science ®Google Scholar
• Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301–1308.
   PubMed Web of Science ®Google Scholar
• Egerton A, Grace AA, Stone J, et al. Glutamate in schizophrenia: neurodevelopmental perspectives and drug development. Schizophr Res. 2020;223:59–70.
   PubMed Web of Science ®Google Scholar
• Goh KK, Wu T-H, Chen C-H, et al. Efficacy of N-methyl-D-aspartate receptor modulator augmentation in schizophrenia: a meta-analysis of randomised, placebo-controlled trials. J Psychopharmacol. 2021;35(3):236–252. DOI:10.1177/0269881120965937
   PubMed Web of Science ®Google Scholar
• Imbrici P, Camerino DC, Tricarico D. Major channels involved in neuropsychiatric disorders and therapeutic perspectives. Front Genet. 2013;4:76.
   PubMedGoogle Scholar
• Grace AA. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Nat Rev Neurosci. 2016;17:524–532.
   PubMed Web of Science ®Google Scholar
• Nakazawa K, Zsiros V, Jiang Z, et al. Gabaergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology. 2012;62(3):1574–1583. doi:10.1016/j.neuropharm.2011.01.022.
   PubMed Web of Science ®Google Scholar
• Rudy B, McBain CJ. Kv3 channels: voltage-gated K+ channels designed for high-frequency repetitive firing. Trends Neurosci. 2001;24(9):517–526.
   PubMed Web of Science ®Google Scholar
• Dienel SJ, Lewis DA. Alterations in cortical interneurons and cognitive function in schizophrenia. Neurobiol Dis. 2019;131:104208.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Burgos G, Cho RY, Lewis DA. Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia. Biol Psychiatry. 2015;77(12):1031–1040.
   PubMed Web of Science ®Google Scholar
• Thelin J, Halje P, Nielsen J, et al. The translationally relevant mouse model of the 15q13.3 microdeletion syndrome reveals deficits in neuronal spike firing matching clinical neurophysiological biomarkers seen in schizophrenia. Acta Physiol (Oxf). 2017;220(1):124–136. DOI:10.1111/apha.12746
   PubMed Web of Science ®Google Scholar
• Benes FM. The GABA system in schizophrenia: cells, molecules and microcircuitry. Schizophr Res. 2015;167(1–3):1–3.
   PubMed Web of Science ®Google Scholar
• Kaar SJ, Angelescu I, Marques TR, et al. Pre-frontal parvalbumin interneurons in schizophrenia: a meta-analysis of post-mortem studies. J Neural Transm (Vienna). 2019;126(12):1637–1651. DOI:10.1007/s00702-019-02080-2
   PubMed Web of Science ®Google Scholar
• Yanagi M, Joho RH, Southcott SA, et al. Kv3.1-containing K(+) channels are reduced in untreated schizophrenia and normalized with antipsychotic drugs. Mol Psychiatry. 2014;19(5):573–579. DOI:10.1038/mp.2013.49
   PubMed Web of Science ®Google Scholar
• Clarke R, Adermark L. Dopaminergic regulation of striatal interneurons in reward and addiction: focus on alcohol. Neural Plast. 2015;2015:1–11.
   Web of Science ®Google Scholar
• Rognli EB, Bramness JG. Understanding the relationship between amphetamines and psychosis. 2015. [cited 2023 Feb 18]. InternetAvailable from Curr Addict Rep. 2(4):285–292. https://doi.org/10.1007/s40429-015-0077-4.
   Google Scholar
• Kokkinou M, Irvine EE, Bonsall DR, et al. Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine. Mol Psychiatry. 2021;26(6):2562–2576. DOI:10.1038/s41380-020-0740-6
   PubMed Web of Science ®Google Scholar
• Parekh PK, Sidor MM, Gillman A, et al. Antimanic Efficacy of a Novel Kv3 Potassium Channel Modulator. Neuropsychopharmacol. 2018;43(2):435–444. DOI:10.1038/npp.2017.155
   PubMed Web of Science ®Google Scholar
• Bionomics. Nov 2022. Corporate Presentation: improving the lives of patients with serious CNS disorders. [Cited 2023 May 31].https://www.bionomics.com.au/wp-content/uploads/2022/11/BNOX-Corporate-Presentation-Nov-2022.pdf
   Google Scholar
• Angelescu I, Kaar SJ, Marques TR, et al. The effect of AUT00206, a Kv3 potassium channel modulator, on dopamine synthesis capacity and the reliability of [18F]-FDOPA imaging in schizophrenia. J Psychopharmacol. 2022;36(9):1061–1069. doi:10.1177/02698811221122031.
   PubMed Web of Science ®Google Scholar
• Kaar SJ, Angelescu I, Nour MM, et al. The effects of AUT00206, a novel Kv3.1/3.2 potassium channel modulator, on task-based reward system activation: a test of mechanism in schizophrenia. Psychopharmacol (Berl). 2022;239(10):3313–3323. doi:10.1007/s00213-022-06216-3.
   PubMed Web of Science ®Google Scholar
• Large C, Modebadze T, Pilati N, et al. ACNP 55th annual meeting: poster session II. Neuropsychopharmacology. 2016;41(S1):S289‐S454.
   Google Scholar
• Deakin B, Perini F, Nazimek J, et al. T108. AUT00206, a novel KV3 channel modulator, reduces ketamine-induced bold signalling in healthy male volunteers: a randomised placebo-controlled crossover trial. Schizophr Bull. [cited 2023 Feb 18]. 2019;45:S245–S246. InternetAvailable from. Supplement_2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455362/10.1093/schbul/sbz019.388
   Google Scholar
• Leger M, Alvaro G, Large C, et al. P.3.C.003 AUT6, a novel Kv3 channel modulator, reverses cognitive and neurobiological dysfunction in a rat model of relevance to schizophrenia symptomatology. Eur Neuropsychopharmacol. 2015;25:S480.
   Web of Science ®Google Scholar
• Bianciardi B, Uhlhaas PJ. Do NMDA-R antagonists re-create patterns of spontaneous gamma-band activity in schizophrenia? A systematic review and perspective. Neurosci Biobehav Rev. 2021;124:308–323.
   PubMed Web of Science ®Google Scholar
• Alegre M, Molero P, Valencia M, et al. Atypical antipsychotics normalize low-gamma evoked oscillations in patients with schizophrenia. Psychiatry Res. 2017;247:214–221.
   PubMed Web of Science ®Google Scholar
• Missonnier P, Prévot A, Herrmann FR, et al. Disruption of gamma–delta relationship related to working memory deficits in first-episode psychosis. J Neural Transm (Vienna). 2020;127(1):103–115. DOI:10.1007/s00702-019-02126-5
   PubMed Web of Science ®Google Scholar
• Hirano Y, Oribe N, Kanba S, et al. Spontaneous Gamma Activity in Schizophrenia. JAMA Psychiatry. 2015;72(8):813–821. DOI:10.1001/jamapsychiatry.2014.2642
   PubMed Web of Science ®Google Scholar
• Mitra S, Nizamie SH, Goyal N, et al. Evaluation of resting state gamma power as a response marker in schizophrenia. Psychiatry Clin Neurosci. 2015;69(10):630–639. DOI:10.1111/pcn.12301
   PubMed Web of Science ®Google Scholar
• Grent-’t-Jong T, Gross J, Goense J, et al. Resting-state gamma-band power alterations in schizophrenia reveal E/I-balance abnormalities across illness-stages. Elife. 2018;7:e37799.
   PubMed Web of Science ®Google Scholar
• Yadav S, Haque Nizamie S, Das B, et al. Resting state quantitative electroencephalogram gamma power spectra in patients with first episode psychosis: an observational study. Asian J Psychiatr. 2021;57:102550.
   PubMed Web of Science ®Google Scholar
• Baradits M, Kakuszi B, Bálint S, et al. Alterations in resting-state gamma activity in patients with schizophrenia: a high-density EEG study. Eur Arch Psychiatry Clin Neurosci. 2019;269(4):429–437. DOI:10.1007/s00406-018-0889-z
   PubMed Web of Science ®Google Scholar
• Large C, Neill J, Harte M, et al. Entraining Neural Networks Through Parvalbumin-Positive Interneurons: can This Offer a Better way to Treat Schizophrenia? Schizophr Bull. [cited 2023 Feb 18]. 2017;43:S3. InternetAvailable from. suppl_1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5475454/
   PubMedGoogle Scholar
• Kaar SJ, Nottage JF, Angelescu I, et al. Gamma oscillations and potassium channel modulation in Schizophrenia: targeting GABAergic Dysfunction. Clin EEG Neurosci. January 2 2023. doi:10.1177/15500594221148643. Online ahead of print.
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370.
   PubMed Web of Science ®Google Scholar
• Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4:28–37.
   PubMedGoogle Scholar
• Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266–1277.
   PubMed Web of Science ®Google Scholar
• Demjaha A, Murray RM, McGuire PK, et al. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012;169:1203–1210.
   PubMed Web of Science ®Google Scholar
• Oldham S, Murawski C, Fornito A, et al. The anticipation and outcome phases of reward and loss processing: a neuroimaging meta-analysis of the monetary incentive delay task. Hum Brain Mapp. 2018;39:3398–3418.
   PubMed Web of Science ®Google Scholar
• Knutson B, Westdorp A, Kaiser E, et al. FMRI visualization of brain activity during a monetary incentive delay task. Neuroimage. 2000;12:20–27.
   PubMed Web of Science ®Google Scholar
• Radua J, Schmidt A, Borgwardt S, et al. Ventral striatal activation during reward processing in psychosis: a neurofunctional meta-analysis. JAMA Psychiatry. 2015;72:1243–1251.
   PubMed Web of Science ®Google Scholar
• Jauhar S, Veronese M, Nour MM, et al. The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: a positron emission tomography study. Biol Psychiatry. 2019;85:79–87.
   PubMed Web of Science ®Google Scholar
• Nucifora FC Jr, Woznica E, Lee BJ, et al. Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019;131:104257.
   PubMed Web of Science ®Google Scholar
• Faden J, Citrome L. Resistance is not futile: treatment-refractory schizophrenia – overview, evaluation and treatment. Expert Opin Pharmacother. 2019;20(1):11–24.
   PubMed Web of Science ®Google Scholar
• Harvey PD, Isner EC. Cognition, social cognition, and functional capacity in early-onset Schizophrenia. Child Adolesc Psychiatr Clin N Am. 2020;29:171–182.
   PubMed Web of Science ®Google Scholar
• Lobo MC, Whitehurst TS, Kaar SJ, et al. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. Neurosci Biobehav Rev. 2022;132:324–361.
   PubMed Web of Science ®Google Scholar